Cargando…
Long-Term Outcomes for Patients With Atypical or Malignant Meningiomas Treated With or Without Radiation Therapy: A 25-Year Retrospective Analysis of a Single-Institution Experience
PURPOSE: Atypical (World Health Organization [WHO] grade 2) and malignant (WHO grade 3) meningiomas have high rates of local recurrence, and questions remain about the role of adjuvant radiation therapy (RT) for patients with WHO grade 2 disease. These patients frequently require salvage therapy, an...
Autores principales: | Kent, Collin L., Mowery, Yvonne M., Babatunde, Olayode, Wright, Ato O., Barak, Ian, McSherry, Frances, Herndon, James E., Friedman, Allan H., Zomorodi, Ali, Peters, Katherine, Desjardins, Annick, Friedman, Henry, Sperduto, William, Kirkpatrick, John P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9133398/ https://www.ncbi.nlm.nih.gov/pubmed/35647401 http://dx.doi.org/10.1016/j.adro.2021.100878 |
Ejemplares similares
-
Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
por: Desjardins, Annick, et al.
Publicado: (2019) -
Adjuvant Radiation in Older Patients With Glioblastoma: A Retrospective Single Institution Analysis
por: Lee, Jessica W., et al.
Publicado: (2021) -
A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab
por: Affronti, Mary Lou, et al.
Publicado: (2016) -
Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma
por: Ghiaseddin, Ashley, et al.
Publicado: (2017) -
Phase II Study to Evaluate the Efficacy and Safety of Rilotumumab and Bevacizumab in Subjects with Recurrent Malignant Glioma
por: Affronti, Mary Lou, et al.
Publicado: (2018)